between the potential value-based prices of future gene therapies and public budget holders’ ability to pay. Budget impact analysis (BIA) plays a role in informing related healthcare decision-making, but does it adequately capture the trade-offs between short term affordability and long-term benefits from such therapies? Our team reviews the approaches to and applications of BIA for gene therapies across various European countries and provides recommendations for its future use.
At OHE, we are also co-leading a project that acknowledges the value of different viewpoints and an interdisciplinary approach to research. Together with the London School of Hygiene and Tropical Medicine (GHECO and CCPH) and the Euro-Mediterranean Centre on Climate Change (CMCC), our Wellcome Trust-funded consortium aims to bridge the gap between how economic evaluation and environmental economics value the health co-benefits of adaptation and mitigation strategies, and to develop globally consistent and accessible guidance on the economic evaluation of the health impacts of climate action.
Our upcoming event “Investing in Innovation: A Spotlight on Haemophilia Therapies” will highlight a difference that is fundamental to OHE’s raison d'être: how do we ensure that future health innovations reconcile the difference between unmet health needs and what is actually possible? This webinar will be useful for a wide range of stakeholders that are interested in health technology assessment, including (but not limited to) payers, patient advocacy groups, regulators, health data scientists, academics, and industry.
Admittedly current changes in international cooperation in the US, and their impact on global health policy and outcomes make it seem that some differences are too hard to reconcile. Now, more than ever, it is important that OHE and others continue their efforts to turn differences into progress.
